The Veri (literally translated as blood in Finnish) wearable device provides users with a simple and effective way of tracking their blood sugar levels. The ultimate goal here is achieving optimal metabolic health, i.e. preventative medicine.
Veri has raised €3.3M across 1 funding round from 5 investors, most recently a Seed round in Jun 2021. Based in Helsinki, Finland; active in Healthtech. Acquired by ŌURA in 2024. Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-06-07 | Seed | €3.3M | Accel,Johannes Schildt,Kristian Ranta,Lifeline Ventures,PROfounders | View deal → |
